Search Results - "MILLER, D. H"

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis by Fisniku, L. K., Brex, P. A., Altmann, D. R., Miszkiel, K. A., Benton, C. E., Lanyon, R., Thompson, A. J., Miller, D. H.

“…Clinically isolated syndromes (CIS), such as optic neuritis, brainstem or spinal cord syndromes are frequently the first clinical presentations of multiple…”
Get full text

Differential diagnosis of suspected multiple sclerosis: a consensus approach by Miller, DH, Weinshenker, BG, Filippi, M, Banwell, BL, Cohen, JA, Freedman, MS, Galetta, SL, Hutchinson, M, Johnson, RT, Kappos, L, Kira, J, Lublin, FD, McFarland, HF, Montalban, X, Panitch, H, Richert, JR, Reingold, SC, Polman, CH

“…Background and objectives Diagnosis of multiple sclerosis (MS) requires exclusion of diseases that could better explain the clinical and paraclinical findings…”
Get full text

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis by O'CONNOR, P. W, GOODMAN, A, KAPPOS, L, LUBLIN, F. D, MILLER, D. H, POLMAN, C, RUDICK, R. A, ASCHENBACH, W, LUCAS, N

“…Due to a heightened risk of progressive multifocal leukoencephalopathy (PML) with increased natalizumab exposure, some physicians interrupt treatment of…”
Get full text

Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI by FARRELL, R. A, ANTONY, D, WALL, G. R, CLARK, D. A, FISNIKU, L, SWANTON, J, KHALEELI, Z, SCHMIERER, K, MILLER, D. H, GIOVANNONI, G

“…Evidence suggests that Epstein-Barr virus (EBV) plays a role in triggering or perpetuating disease activity in multiple sclerosis (MS). We investigated 100…”
Get full text

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes by KAPPOS, L, POLMAN, C. H, POHL, C, SANDBRINK, R, FREEDMAN, M. S, EDAN, G, HARTUNG, H. P, MILLER, D. H, MONTALBAN, X, BARKHOF, F, BAUER, L, JAKOBS, P

“…To assess efficacy, safety, and tolerability of every-other-day interferon beta-1b treatment in patients with a first clinical event suggestive of multiple…”
Get full text

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis by Montalban, X., Gold, R., Thompson, A. J., Otero‐Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comi, G., Derfuss, T., Fazekas, F., Hartung, H. P., Havrdova, E., Hemmer, B., Kappos, L., Liblau, R., Lubetzki, C., Marcus, E., Miller, D. H., Olsson, T., Pilling, S., Selmaj, K., Siva, A., Sorensen, P. S., Sormani, M. P., Thalheim, C., Wiendl, H., Zipp, F.

“…Background and purpose Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is therefore a need for a…”
Get full text

MRI criteria for MS in patients with clinically isolated syndromes by MONTALBAN, X, TINTORE, M, ROVARIS, M, DE STEFANO, N, THOMPSON, A, YOUSRY, T, ROVIRA, A, MILLER, D. H, SWANTON, J, BARKHOF, F, FAZEKAS, F, FILIPPI, M, FREDERIKSEN, J, KAPPOS, L, PALACE, J, POLMAN, C

“…In recent years, criteria for the diagnosis of multiple sclerosis (MS) have changed, mainly due to the incorporation of new MRI criteria. While the new…”
Get full text

Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration by Kearney, H, Rocca, MA, Valsasina, P, Balk, L, Sastre-Garriga, J, Reinhardt, J, Ruggieri, S, Rovira, A, Stippich, C, Kappos, L, Sprenger, T, Tortorella, P, Rovaris, M, Gasperini, C, Montalban, X, Geurts, JJG, Polman, CH, Barkhof, F, Filippi, M, Altmann, DR, Ciccarelli, O, Miller, DH, Chard, DT

“…Background: Understanding long-term disability in multiple sclerosis (MS) is a key goal of research; it is relevant to how we monitor and treat the disease…”
Get full text

Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes by DE STEFANO, N, GIORGIO, A, DINACCI, D, TEDESCHI, G, GASS, A, MONTALBAN, X, ROVIRA, A, THOMPSON, A, COMI, G, MILLER, D. H, FILIPPI, M, BATTAGLINI, M, ROVARIS, M, SORMANI, M. P, BARKHOF, F, KORTEWEG, T, ENZINGER, C, FAZEKAS, F, CALABRESE, M

“…To assess the time course of brain atrophy and the difference across clinical subtypes in multiple sclerosis (MS). The percent brain volume change (PBVC) was…”
Get full text

Diffusion MRI in multiple sclerosis by ROVARIS, M, GASS, A, BAMMER, R, HICKMAN, S. J, CICCARELLI, O, MILLER, D. H, FILIPPI, M

“…Diffusion imaging is a quantitative, MR-based technique potentially useful for the study of multiple sclerosis (MS), due to its increased pathologic…”
Get full text

Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome by Brownlee, WJ, Altmann, DR, Alves Da Mota, P, Swanton, JK, Miszkiel, KA, Wheeler-Kingshott, CAM Gandini, Ciccarelli, O, Miller, DH

“…Background: Spinal cord pathology is an important substrate for long-term disability in multiple sclerosis (MS). Objective: To investigate longitudinal changes…”
Get full text

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS by MILLER, D. H, SOON, D, KAPPOS, L, HUTCHINSON, M, HAVRDOVA, E, LUBLIN, F. D, GIOVANNONI, G, WAJGT, A, RUDICK, R, LYNN, F, PANZARA, M. A, SANDROCK, A. W, FERNANDO, K. T, MACMANUS, D. G, BARKER, G. J, YOUSRY, T. A, FISHER, E, O'CONNOR, P. W, PHILLIPS, J. T, POLMAN, C. H

“…In a 2-year, placebo-controlled trial (the Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis [AFFIRM] study), involving 942 patients…”
Get full text

GLANCE : Results of a phase 2, randomized, double-blind, placebo-controlled study by GOODMAN, A. D, ROSSMAN, H, PANZARA, M. A, SANDROCK, A. W, BAR-OR, A, MILLER, A, MILLER, D. H, SCHMIERER, K, LUBLIN, F, KHAN, O, BORMANN, N. M, YANG, M

“…To evaluate the safety and tolerability of natalizumab when added to glatiramer acetate (GA) in patients with relapsing multiple sclerosis. The primary outcome…”
Get full text

Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance by Miller, David H., Barkhof, Frederik, Frank, Joseph A., Parker, Geoffrey J. M., Thompson, Alan J.

“…MRI methods are widely used to follow the pathological evolution of multiple sclerosis in life and its modification by treatment. To date, measures of the…”
Get full text

Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes by Swanton, J K, Fernando, K, Dalton, C M, Miszkiel, K A, Thompson, A J, Plant, G T, Miller, D H

“…Background: The McDonald criteria include MRI evidence for dissemination in space and dissemination in time for the diagnosis of multiple sclerosis in young…”
Get full text

Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis by MILLER, D. H, THOMPSON, A. J, FILIPPI, M

“…Magnetic resonance (MR) techniques are of value in following the pathological process of multiple sclerosis in vivo. They are widely applied to monitor the…”
Get full text

MRI T2 lesion burden in multiple sclerosis : A plateauing relationship with clinical disability by LI, D. K. B, HELD, U, WOLINSKY, J. S, FILIPPI, M, PETKAU, J, DAUMER, M, BARKHOF, F, FAZEKAS, F, FRANK, J. A, KAPPOS, L, MILLER, D. H, SIMON, J. H

“…Previous studies have shown only modest correlation between multiple sclerosis (MS) lesions on MRI and clinical disability. To investigate the relationship…”
Get full text

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy by STÜVE, O, CRAVENS, P. D, MACMANUS, D, MILLER, D. H, RADÜ, E. W, CAMERON, E. M, MONSON, N. L, ZHANG, S, KIM, R, HEMMER, B, FROHMAN, E. M, PHILLIPS, J. T, REMINGTON, G. M, VON GELDERN, G, CEPOK, S, SINGH, M. P, COHEN TERVAERT, J. W, DE BAETS, M

“…Natalizumab is a humanized recombinant monoclonal antibody against very late activation antigen-4 approved for the treatment of patients with multiple…”
Get full text

Brain atrophy in clinically early relapsing-remitting multiple sclerosis by CHARD, D. T, GRIFFIN, C. M, PARKER, G. J. M, KAPOOR, R, THOMPSON, A. J, MILLER, D. H

“…Brain atrophy measured by MRI is a potentially useful tool for monitoring disease progression in multiple sclerosis. The location, extent and mechanisms of…”
Get full text

A comprehensive assessment of cerebellar damage in multiple sclerosis using diffusion tractography and volumetric analysis by Anderson, VM, Wheeler-Kingshott, CAM, Abdel-Aziz, K, Miller, DH, Toosy, A, Thompson, AJ, Ciccarelli, O

“…Background: White matter (WM) and grey matter (GM) brain damage in multiple sclerosis (MS) is widespread, but the extent of cerebellar involvement and impact…”
Get full text